Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04378907 · ClinicalTrials.gov registry record · NA
Assessing Electronic Cigarette Nicotine Flux
A NA study of Electronic Cigarette Use, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04378907: Completed NA study of Electronic Cigarette Use, sponsored by Virginia Commonwealth University.
NCT04378907 is a NA study of Electronic Cigarette Use that has completed, run by Virginia Commonwealth University. The registered enrollment target is 33 participants, below the 210-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04378907, a NA study of Electronic Cigarette Use, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.
Primary Outcome
Blood will be taken during each session (5) to examine changes from baseline to immediately follow a ten-puff bout. There is one arm, but 4 different conditions per outcome. One subject with/ missing plasma samples was removed from analysis.
Conditions Studied
Interventions
- OTHER Cigarette Smoker/ECIG users: 0 mg/ml nicotine concentration
- OTHER Cigarette Smokers/ECIG users: 6 mg/ml nicotine concentration
- OTHER Cigarette Smokers/ECIG users: 15 mg/ml nicotine concentration
- OTHER Cigarette Smokers/ECIG users: 30 mg/ml nicotine concentration
Study Locations (1)
Virginia
- Center for the Study of Tobacco Products - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2023-02-01 |
| Phase | NA |
What the finished NCT04378907 record still lists
NCT04378907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 210-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Electronic Cigarette Use appearing as the primary indexed condition, and to 4 interventions - of which Cigarette Smoker/ECIG users: 0 mg/ml nicotine concentration is the first listed.
NCT04378907 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04378907 about?
NCT04378907 is a clinical study titled "Assessing Electronic Cigarette Nicotine Flux". The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.
What is the current status of trial NCT04378907?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2021-01-05. Estimated completion is 2023-02-01.
What conditions does trial NCT04378907 study?
This clinical trial studies the following conditions: Electronic Cigarette Use.
What interventions are being tested in trial NCT04378907?
The interventions under investigation include: Cigarette Smoker/ECIG users: 0 mg/ml nicotine concentration (OTHER), Cigarette Smokers/ECIG users: 6 mg/ml nicotine concentration (OTHER), Cigarette Smokers/ECIG users: 15 mg/ml nicotine concentration (OTHER), Cigarette Smokers/ECIG users: 30 mg/ml nicotine concentration (OTHER).
Who is sponsoring clinical trial NCT04378907?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04378907 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Electronic Cigarette Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04378907's enrollment target sits among peer trials
33 12th of 15 higher than 4 of 15 other Electronic Cigarette Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Electronic Cigarette Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Social Media Use on Young Adults' E-Cigarette Use
RECRUITING · NA
-
Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC
RECRUITING · NA
-
Effect of Menthol on ENDS Users' Addiction and Exposure
RECRUITING · NA
-
Developing and Testing Health Warning Labels on the ENDS Device
RECRUITING · NA
-
Development of UP2UTobacco for High School Youth
ACTIVE NOT RECRUITING · NA
-
PACE Vape Messaging Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI